Simon N. Haydar - Concepedia

Author

Simon N. Haydar

Siena Biotech (Italy)

Also Known As

Haydar, S.N., S. Haydar, S. N. HAYDAR, S. N. Haydar, S.N. Haydar, Simon Haydar, Simon N. Haydar, Simon N. Haydar,

Publications

459

Citations

H-Index

Concepts

All Affiliations

Siena Biotech (Italy)Pfizer (United States)Princeton University

About

Simon N. Haydar is an author at Siena Biotech (Italy) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	153
2	Biochemistry	6	6	133
3	Natural Sciences	3	3	60
4	Neurology	2	2	44
5	Social Sciences	1	1	20

Simon N. Haydar

Publications

311

Citations

H-Index

Page 1

	Year	Citations
Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders Renza Roncarati, Carla Scali, Thomas A. Comery, Journal of Pharmacology and Experimental Therapeutics	2009	99
SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist Simon N. Haydar, Chiara Ghiron, Laura Bettinetti, Bioorganic & Medicinal Chemistry BiochemistryFunctional SelectivityMedicineNicotinePhysiology	2009	41
Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonists Containing a Urea Moiety: Identification and Characterization of the Potent, Selective, and Orally Efficacious Agonist 1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) Urea (SEN34625/WYE-103914) Chiara Ghiron, Simon N. Haydar, Suzan Aschmies, Journal of Medicinal Chemistry Brain PenetrationPharmacotherapyMedicinal ChemistryNicotineNeurology	2010	30
Discovery of a Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonist Series and Characterization of the Potent, Selective, and Orally Efficacious Agonist 5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid [5-(4-Methoxyphenyl)-1H-pyrazol-3-yl] Amide (SEN15924, WAY-361789) Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, Journal of Medicinal Chemistry	2012	26
5-Cyclic Amine-3-arylsulfonylindazoles as Novel 5-HT<sub>6</sub> Receptor Antagonists Simon N. Haydar, Heedong Yun, Patrick M. Andrae, Journal of Medicinal Chemistry	2010	22
Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor Arianna Nencini, Cristiana Castaldo, Thomas A. Comery, European Journal of Medicinal Chemistry BiochemistryMedicineNicotineHybrid SeriesReceptor (Biochemistry)	2014	21
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625 Karen L. Marquis, Thomas A. Comery, Flora Jow, Psychopharmacology Neuropsychological FunctioningPsychiatryPsychotic DisorderMedicineDementia	2011	20
Heterobiaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part II Michael P. Trova, Keith D. Barnes, Luis Alicea, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryHeterobiaryl Purine DerivativesHeterocyclicBiochemistryMedicine	2009	16
<i>N</i>-[5-(5-Fluoropyridin-3-yl)-1<i>H</i>-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, Journal of Medicinal Chemistry Drug TargetPharmacotherapyPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2012	14
1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-pyrrolopyridines are 5-HT6 receptor ligands Ronald C. Bernotas, Schuyler Antane, Steven Lenicek, Bioorganic & Medicinal Chemistry Letters 5-Ht6 Receptor LigandsBiochemistryFunctional SelectivityReceptor (Biochemistry)Non-peptide Ligand	2009	11

Page 1